Drug Trial Radar · NCT04834973
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
May 7, 2021
Primary completion
Jul 12, 2022
Study completion Jul 12, 2022
Sponsor
- Lead sponsor
- QBiotics Group LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety, tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination with intravenous pembrolizumab in adult patients with unresectable, Stage IIIB to IV M1c melanoma.
Conditions
- Melanoma
Interventions
tigilanol tiglateDrug
Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2. Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
pembrolizumabDrug
Three weekly 200 mg intravenous pembrolizumab treatment. Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Dose LevelTime frame: 12 months
- Determine incidence of Treatment Emergent Adverse EventsTime frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Cairns and Hinterland Hospital and Health Service
Cairns, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.